Who is sponsoring NCT03028324?

NCT03028324 is sponsored by University of Miami.

What drugs are being tested in NCT03028324?

Interventions in NCT03028324: Transcranial Magnetic Stimulation (TMS).

What condition does NCT03028324 study?

NCT03028324 studies Apraxia Speech.

Is NCT03028324 still recruiting?

NCT03028324 is currently terminated. Last updated 26 May 2020.

Are results published for NCT03028324?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-05-26 · How we verify

NCT03028324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)

Terminated NA Results posted Last updated 26 May 2020

What this trial tests

NA trial testing Transcranial Magnetic Stimulation (TMS) in Apraxia Speech in 4 participants. Terminated before completion.

Timeline

9 August 2017

Primary endpoint
13 November 2018

13 November 2018

Quick facts

Lead sponsor	University of Miami
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	4
Start date	9 August 2017
Primary completion	13 November 2018
Estimated completion	13 November 2018
Sites	1 location across United States

Drugs / interventions tested

Transcranial Magnetic Stimulation (TMS)

Conditions studied

Apraxia Speech — all drugs for Apraxia Speech →

Sponsor

University of Miami

Who can join

18 and older, any sex, with Apraxia Speech. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Speech Performance Primary · Baseline, 4 weeks

Apraxia of Speech Rating Scale has a total range from 0-64, with lower scores indicating lower impairment and higher scores indicating higher impairment.

Group	Value	95% CI
Transcranial Magnetic Stimulation (TMS)	-8.75	± 8.06

Sponsor's own description

The purpose of this study is to assess the influence of transcranial magnetic stimulation (TMS) on speech performance in individuals with primary progressive apraxia of speech.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcranial Magnetic Stimulation (TMS)

Trials testing the same drug.

NCT05861284 — Developing and Optimizing Transcranial Magnetic Stimulation for Motor Rehabilitation · NA · withdrawn
NCT07250464 — Motor Evoked Potential and Cortical Silent Period in Migraine · NA · not yet recruiting
NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
NCT06960083 — Transcranial Magnetic Stimulation in Misophonia · NA · recruiting
NCT07179406 — The Effect of Spinal Cord Stimulators on Restless Leg Syndrome · NA · recruiting

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03028324 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 26 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03028324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing